Foundayo vs the Wegovy Pill: How the Two Oral GLP-1s Compare
Two licensed daily tablets, two months apart. How they differ on food rules, dosing, trial results, side effects and UK access—including where the evidence doesn't support a clean comparison.
Part of the Overweight and Obesity condition guide.
The headline: The Wegovy pill was licensed in the UK on 11 June 2026 and Foundayo on 10 August 2026. The single biggest practical difference between them isn't effectiveness—it's that Wegovy tablets require a fasted morning routine with a 30-minute wait, and Foundayo requires nothing at all.
Compare Both Tablets with a Prescriber
Access Doctor provides both licensed GLP-1 tablets following a GPhC-regulated online consultation with our pharmacist independent prescribers, who'll help you weigh up which suits your routine.
Order Foundayo →The two tablets side by side
For years, GLP-1 medicines for weight management meant injections. In the space of two months, the UK licensed two daily tablets: the Wegovy pill (oral semaglutide 25 mg) on 11 June 2026, and Foundayo (orforglipron) on 10 August 2026.
| Foundayo | Wegovy pill | |
|---|---|---|
| Active ingredient | Orforglipron | Semaglutide (oral) |
| Drug type | Small-molecule, non-peptide GLP-1 receptor agonist | Peptide GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| UK approval | 10 August 2026 | 11 June 2026 |
| Form | Daily tablet | Daily tablet |
| Food and water rules | None—any time, with or without food | Empty stomach, morning, up to 120 ml water, wait 30 minutes |
| Tablet strengths | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | 1.5, 4, 9, 25 mg |
| Titration | Monthly steps, up to 5 increases | Monthly steps, up to 3 increases |
| Also licensed for | Type 2 diabetes | Weight management only in the UK |
| NHS availability | No | No |
Both are prescription-only medicines. Neither can be supplied without a prescription following a clinical assessment, and neither is currently available on the NHS. This page is general information, not a recommendation.
The biggest practical difference: how you take it
This is where the two medicines genuinely diverge, and for many people it'll matter more than any difference in average weight loss.
The Wegovy pill has strict administration rules
Semaglutide is a peptide. Peptides are destroyed by digestion, which is why semaglutide has historically been injected. The oral version gets around this using an absorption enhancer—but only if the stomach is genuinely empty and there's very little liquid present. So:
- Take it in the morning, on an empty stomach, after an overnight fast
- Swallow it whole with no more than about 120 ml of water (roughly 4 fl oz)
- Then wait at least 30 minutes before eating, drinking anything else, or taking any other oral medicine
These aren't suggestions. Absorption of oral semaglutide is low and variable at the best of times, and getting the routine wrong reduces how much of the drug reaches your bloodstream.
Foundayo has none of them
Orforglipron is a small non-peptide molecule that survives digestion on its own. There's no absorption enhancer, no fasting requirement, and no waiting period. You take it once a day, at any time, with or without food.
Who the 30-minute rule actually matters for
The rule sounds trivial and often isn't. It's a real obstacle if you:
- take other morning medicines, particularly thyroid medication such as levothyroxine, which has its own fasting requirement
- work shifts or have an irregular schedule
- have young children or care responsibilities in the morning
- travel across time zones regularly
- have simply tried a medicine with a fasting routine before and know you won't stick to it
Adherence isn't a side issue with these medicines. A tablet taken correctly four days a week is likely to work less well than one taken correctly every day. The medicine you'll actually take isn't always the one with the better headline number.
What the trials showed
Here's where most comparison articles go wrong. Foundayo and the Wegovy pill have never been compared head-to-head. The figures below come from separate trials, run by different companies, in different populations, over different lengths of time.
Foundayo — ATTAIN-1
3,127
Adults enrolled, over 72 weeks
−11.1%
Average weight change at 17.2 mg (treatment-policy), vs −2.1% placebo
71.5%
Lost at least 5% of body weight, vs 26.8% on placebo
Eli Lilly also reports −12.4% using the efficacy estimand.
Wegovy pill — OASIS-4
307
Adults enrolled, over 64 weeks on treatment
−13.6%
Average weight change at 25 mg (treatment-policy), vs about −2% placebo
30%
Lost at least 20% of body weight, vs 3% on placebo
Novo Nordisk reports −16.6% when treatment was adhered to (efficacy estimand).
The caveats that matter
Two different estimands
The treatment-policy estimand counts everyone as randomised, including people who stopped. The efficacy estimand estimates the effect in people who take it as intended. Comparing one drug's efficacy figure with another's treatment-policy figure inflates the gap, and press coverage does it constantly.
Very different trial sizes
ATTAIN-1 enrolled 3,127 people; OASIS-4 enrolled 307. A smaller trial gives a less precise estimate, with wider uncertainty around the average.
Different durations
72 weeks versus 64 weeks on treatment. Weight loss on GLP-1 medicines typically continues for a period before plateauing.
Different populations
OASIS-4 was 79% women and 92% white, with a mean age of 48. Trial populations shape results.
So what can you honestly say?
On the available evidence, oral semaglutide 25 mg appears to produce greater average weight loss than orforglipron at its highest dose. The gap looks meaningful and points in the same direction whichever estimand you use.
What you can't say is by exactly how much, or that it holds for any individual. Response to GLP-1 medicines varies enormously between people. In both trials, a substantial minority lost very little, and a substantial minority lost a great deal. There's currently no reliable way to know in advance which group you fall into, and no evidence at all about whether someone who responds poorly to one of these medicines would do better on the other. A head-to-head trial would settle much of this. None has been published.
How the side effect profiles compare
Both medicines belong to the same drug class and share the same broad safety profile. The commonest side effects for both are gastrointestinal—nausea, constipation, diarrhoea, vomiting, indigestion—worst after each dose increase, easing with time.
| Foundayo (17.2 mg) | Wegovy pill (25 mg) | |
|---|---|---|
| Nausea | 35% (placebo 10%) | — |
| Constipation | 24% (placebo 9%) | — |
| Diarrhoea | 25% (placebo 11%) | — |
| Vomiting | 24% (placebo 4%) | — |
| Any gastrointestinal event | — | 74% (placebo 42%) |
| Stopped due to side effects | 10.3% (placebo 2.7%) | 7% (placebo 6%) |
The two trials reported adverse events differently, so the individual rows aren't directly comparable—which is why the table has gaps rather than invented numbers. The discontinuation rates are the most comparable figures, and on those, tolerability looks broadly similar.
Shared serious risks
Both carry a boxed warning for thyroid C-cell tumours and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2 syndrome. Both carry warnings for pancreatitis, gallbladder disease, dehydration and acute kidney injury, hypoglycaemia when combined with insulin or a sulfonylurea, worsening diabetic retinopathy, and aspiration risk under anaesthesia—tell any surgeon, anaesthetist, endoscopist or dentist well before a procedure. Neither should be taken in pregnancy or alongside another GLP-1 receptor agonist.
Where the interaction profiles differ
This is a genuine, under-discussed difference.
Foundayo is metabolised via CYP3A4, which creates specific interactions: the maximum dose drops to 9 mg daily with a strong CYP3A4 inhibitor, strong inducers such as rifampicin, carbamazepine and St John's wort should be avoided, and simvastatin must be limited to 20 mg daily.
The Wegovy pill's interaction issue is different and more about timing—it delays gastric emptying and requires a 30-minute window clear of all other oral medicines, which affects anything you take in the morning.
Both can reduce the absorption of oral contraceptives. With Foundayo, the labelling advises additional non-oral contraception for 30 days after starting and after every dose increase. If you use oral contraception, raise this specifically—it's one of the most commonly missed points about both medicines, and our guide to alternatives to the contraceptive pill covers the non-oral options.
Why neither tablet is on the NHS
Neither medicine is available on the NHS. In both cases MHRA authorisation confirms safety, quality and efficacy; NHS funding is a separate decision made by NICE, and no appraisal has concluded for either. Access is currently through private prescription only.
A UK price for Foundayo hadn't been confirmed by the manufacturer at the time of writing, so any specific monthly figure circulating online is an estimate. Wegovy tablet pricing is established—see Wegovy pills UK cost. When comparing, look at the total annual cost at a realistic maintenance dose, including consultations and monitoring, not just the medicine at its starting strength.
Which tablet suits which person
The Wegovy pill may suit you better if
The evidence of greater average weight loss is your priority, your mornings are predictable enough to accommodate the fasting routine, and you don't take other morning medicines that would conflict.
Foundayo may suit you better if
An unstructured routine, shift work or travel makes the fasting rules unrealistic, you take other oral medicines that are awkward to time around, or you've previously struggled with adherence on a medicine with a strict routine.
Neither may be right if you have a contraindication, are pregnant or trying to conceive, or haven't yet had a proper assessment of why weight management has been difficult. Both are licensed as an adjunct to diet and physical activity—every trial participant received lifestyle support alongside the medicine, and the results describe the combination.
Order the Tablet That Fits Your Routine
A free online consultation with a GPhC-registered pharmacist independent prescriber, who will discuss which of the two licensed GLP-1 tablets is the better clinical and practical fit for you. Dispensed by our UK pharmacy with discreet delivery.
Compare Weight Loss Treatments →Frequently Asked Questions
Which is more effective, Foundayo or the Wegovy pill?
On current evidence, oral semaglutide 25mg produced greater average weight loss in its trial than orforglipron did in its own. The two medicines have never been compared head to head, and the trials differed substantially in size, duration and population, so the difference cannot be quantified precisely. Averages also do not predict individual results, and response to GLP-1 medicines varies widely from person to person.
What is the biggest practical difference between Foundayo and Wegovy tablets?
How you take them. Wegovy tablets must be taken in the morning on an empty stomach, with no more than about 120ml of water, followed by a wait of at least 30 minutes before eating, drinking or taking any other oral medicine. Foundayo has none of those rules and can be taken at any time of day, with or without food. For many people that difference matters more than any difference in average weight loss.
Can I switch from one oral GLP-1 to the other?
That is a clinical decision for your prescriber. The two should never be taken together, because they are both GLP-1 receptor agonists. There is no published evidence on whether switching between them helps people who respond poorly to one, so a switch is usually made for tolerability or routine rather than in the expectation of a better result.
Can I switch from Wegovy injections to the Wegovy pill?
People being treated with the 2.4mg weekly semaglutide injection can transition to the 25mg daily tablet. The timing and the starting strength should be directed by your prescriber, and if you are on a lower injection dose or a different GLP-1 medicine the answer may be different. Never change the form or dose of your treatment without discussing it with a prescriber first.
Is the Wegovy pill the same as Rybelsus?
Both are oral semaglutide, but they are different products at different doses with different licences. Rybelsus is licensed in the UK for type 2 diabetes and tops out well below the 25mg strength used for weight management. Wegovy tablets are licensed for weight management. Prescribing Rybelsus purely for weight loss would be off label use.
Is either Foundayo or the Wegovy pill available on the NHS?
No. MHRA authorisation confirms that a medicine is safe, effective and of adequate quality, but NHS funding is a separate decision made by NICE, and no appraisal has concluded for either tablet. Access to both is currently by private prescription only, following a consultation with a registered prescriber.
Which of the two has fewer side effects?
The two trials reported adverse events too differently for a reliable comparison. The most comparable figures are the discontinuation rates: about 10.3% of people stopped Foundayo at its highest dose because of side effects, against 7% for the Wegovy pill in its own trial. Both are dominated by gastrointestinal effects that peak after each dose increase and then ease.
Are there tablets that work as well as the injections?
Not on current evidence. Injectable tirzepatide has produced substantially larger average weight loss in its own trials than either tablet in theirs. The advantage of these tablets is the route of administration rather than a greater effect, and for people who would not start or continue an injection that can still be the more useful medicine.
Choosing between the two with Access Doctor
Access Doctor is a GPhC-registered UK online pharmacy supplying both licensed GLP-1 tablets by private prescription. The consultation is free and reviewed by a pharmacist independent prescriber, who'll take your routine, other medicines and medical history into account rather than simply issuing what you select. There's no obligation to order.
Weight Loss · Rx
Foundayo (Orforglipron)
Once-daily tablet, any time of day, with or without food. No fasting routine.
View product →Weight Loss · Rx
Wegovy Tablets
Once-daily oral semaglutide up to 25 mg, taken fasted each morning.
View product →Or see every option side by side on our weight loss treatments page.
References
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026. gov.uk
- The Pharmaceutical Journal. MHRA approves semaglutide oral tablets for weight loss. 2026. pharmaceutical-journal.com
- US Food and Drug Administration. FOUNDAYO (orforglipron) tablets — Prescribing Information. 2026. accessdata.fda.gov
- American College of Cardiology. OASIS 4 trial summary. 2025. acc.org
- Eli Lilly and Company. Complete ATTAIN-1 results published in the New England Journal of Medicine. 2026. lilly.gcs-web.com
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. In a medical emergency, call 999.